|
|
|||||||||||
SHORT REPORTS |
University of Oxford Centre for Clinical Magnetic Resonance Research, John Radcliffe Hospital, Oxford
University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, UK
Correspondence: Correspondence: Dr Ray Norbury, University of Oxford Centre for Clinical Magnetic Resonance Research, MRS Unit, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK. Email: raymond.norbury{at}psych.oxford.ac.uk
We used functional magnetic resonance imaging to investigate the effects of short-term treatment with reboxetine, a selective noradrenaline reuptake inhibitor, on emotional facial processing in healthy volunteers. Reboxetine was associated with a reduced amygdala response to fearful faces and increased activation to happy v. neutral facial expressions in the right fusiform gyrus, relative to placebo treatment and in the absence of changes in mood. Our results show that reboxetine modulates the neural substrates of emotional processing, highlighting a mechanism by which drug treatment could normalise negative bias in depression and anxiety.
This article has been cited by other articles:
![]() |
S. HAFIZI, P. CHANDRA, and J. COWEN Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations The British Journal of Psychiatry, October 1, 2007; 191(4): 282 - 284. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |